{"organizations": [], "uuid": "116126a30cca78e5e38bd72ea8b6bd5ebe0ae825", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-merck/merck-seeks-to-arbitrate-zetia-pay-for-delay-cases-idUSL2N1RH00E", "country": "US", "domain_rank": 408, "title": "Merck seeks to arbitrate Zetia 'pay-for-delay' cases", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.988, "site_type": "news", "published": "2018-04-04T08:10:00.000+03:00", "replies_count": 0, "uuid": "116126a30cca78e5e38bd72ea8b6bd5ebe0ae825"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-merck/merck-seeks-to-arbitrate-zetia-pay-for-delay-cases-idUSL2N1RH00E", "ord_in_thread": 0, "title": "Merck seeks to arbitrate Zetia 'pay-for-delay' cases", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "negative"}], "locations": [{"name": "virginia", "sentiment": "none"}, {"name": "norfolk", "sentiment": "none"}], "organizations": [{"name": "merck & co inc", "sentiment": "negative"}, {"name": "westlaw", "sentiment": "none"}, {"name": "zetia", "sentiment": "none"}, {"name": "glenmark pharmaceuticals ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Merck & Co Inc is urging a judge to force a group of drug distributors to arbitrate antitrust cases alleging the pharmaceutical company entered into a patent settlement that delayed the release of generic version of anti-cholesterol drug Zetia.\nMerck filed motions on Monday in federal court in Norfolk, Virginia, in an effort to dodge proposed class action lawsuits accusing it of entering into a 2010 “pay-for-delay” deal with generic drug maker Glenmark Pharmaceuticals Ltd over Zetia, sales of which were in the billions at the time.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2GuxhBq\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://bit.ly/2GuxhBq", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://instagram.com/reuters/"], "published": "2018-04-04T08:10:00.000+03:00", "crawled": "2018-04-04T12:30:58.006+03:00", "highlightTitle": ""}